A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2002
10/10/2002	US20020146749 Diagnosis and treatment of neuroectodermal tumors
10/10/2002	US20020146466 Solid form compositions containing an extract of a raw material as the active ingredient and process of preparing the same
10/10/2002	US20020146450 Liposome-entrapped topoisomerase inhibitors
10/10/2002	US20020146448 B-glucans encapsulated in liposomes
10/10/2002	US20020146426 Administering molecule joined to a heat shock protein or molecule joined to an adenosinetriphosphate (ATP) binding domain of a heat shock protein inducing an immune response that includes a CD8+ cytotoxic T lymphocyte (CTL) response
10/10/2002	US20020146421 Diagnosis and treatment of malignant neoplasms
10/10/2002	US20020146417 Administering function blocking antibody or a fragment antibody, capable of binding an epitope of VLA-1 to provide a decrease in arthritic score of about 65% or greater when compared to control antibody treated subject
10/10/2002	US20020146416 Human trk receptors and neurotrophic factor inhibitors
10/10/2002	US20020146408 Human haemopoietic maturation factor
10/10/2002	US20020146397 Unblocking immunization at a regional lymph node by: promoting differentiation and maturation of immature dendritic cells in a regional lymph node and; allowing presentation by resulting mature dendritic cells of antigen to T-cells
10/10/2002	US20020146396 Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells
10/10/2002	US20020146389 For inducing apoptosis in mammalian cancer cells; stimulating a proinflammatory response in mammalian cells
10/10/2002	DE10117381A1 Herstellung polyklonaler, monospezifischer Antikörper gegen die uPAR-Varianten del4, del5 und del4+5 sowie deren Verwendung für diagnostische und therapeutische Zwecke Production of polyclonal, monospecific antibodies to uPAR variants del4, del5 and del4 + 5 and their use for diagnostic and therapeutic purposes
10/10/2002	DE10117204A1 In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel In the 6-position substituted indolinones, their preparation and their use as medicaments
10/10/2002	DE10116589A1 Use of creatine for reducing oxidative stress e.g. for treating aging, neurodegeneration and cancers
10/10/2002	DE10115922A1 Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung Cyclic substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use
10/10/2002	DE10114775A1 2-Mercapto-4,5-diarylimidazolderivate und ihre Verwendung in der Pharmazie 2-mercapto-4,5-diarylimidazolderivate and their use in the pharmaceutical
10/10/2002	DE10112851C1 Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen Semi-allogeneic anti-tumor vaccine with HLA haplo-identical antigen presenting cells
10/10/2002	CA2455915A1 Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
10/10/2002	CA2452152A1 Use of cyclopamine in the treatment of psoriasis
10/10/2002	CA2443338A1 Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof
10/10/2002	CA2443138A1 Anti-muc-1 single chain antibodies for tumor targeting
10/10/2002	CA2443045A1 Mucin peptide with immunoenhancing properties
10/10/2002	CA2442801A1 Recombinant antibodies coexpressed with gntiii
10/10/2002	CA2442775A1 New polynucleotides and polypeptides of the ifn alpha-21 gene
10/10/2002	CA2442619A1 Cancer-testis antigens
10/10/2002	CA2442531A1 Peptides and antibodies to muc 1 proteins
10/10/2002	CA2442495A1 Alpha conotoxin peptides with analgesic properties
10/10/2002	CA2442484A1 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
10/10/2002	CA2442482A1 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
10/10/2002	CA2442455A1 A method of treating proliferative diseases using eg5 inhibitors
10/10/2002	CA2442428A1 Novel tyrosine kinase inhibitors
10/10/2002	CA2442354A1 New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds
10/10/2002	CA2442106A1 Conjugated unsaturated glyceride mixtures and a method for producing the same
10/10/2002	CA2442064A1 G-protein coupled receptors
10/10/2002	CA2442062A1 Secreted proteins
10/10/2002	CA2442020A1 Methods of delivery of exogenous proteins to the cytosol and uses thereof
10/10/2002	CA2441970A1 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
10/10/2002	CA2441863A1 Drugs containing genetically modified antibody against ganglioside gd3
10/10/2002	CA2441654A1 Cytoskeleton-associated proteins
10/10/2002	CA2441562A1 Short bioactive peptides and methods for their use
10/10/2002	CA2441335A1 Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
10/10/2002	CA2441252A1 Estrogen replacement therapy
10/10/2002	CA2440831A1 Combination therapy using cd40 and cd20 ligands
10/10/2002	CA2440228A1 Inhibitors of cyclin dependent kinases as anti-cancer agent
10/10/2002	CA2440108A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/10/2002	CA2439842A1 Gaba-receptor modulators for the treatment of neurodegenerative diseases of the eye
10/10/2002	CA2438272A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
10/10/2002	CA2435390A1 Compositions, methods and apparatuses for singlet oxygen delivery
10/10/2002	CA2433910A1 Antibiotics from bacteria isolated from amphibian skin
10/10/2002	CA2430684A1 Micromonospora echinospora genes encoding for biosynthesis of calicheamicin and self-resistance thereto
10/09/2002	EP1247865A2 Antibody for use in therapy
10/09/2002	EP1247810A1 Novel benzotriazoles anti-inflammatory compounds
10/09/2002	EP1247803A2 Indolinone compounds suitable for modulation of protein kinases
10/09/2002	EP1247529A1 Physiologically active substance eem-s originating in mushrooms, process for producing the same and drugs
10/09/2002	EP1247524A1 Composition comprising taurolidine and/or taurultam for the treatment of cancer
10/09/2002	EP1247458A2 Composition for drinking/eating and beverage/food comprising agaricus blazei murrill
10/09/2002	EP1246946A2 Compositions and methods for the discovery and selection of biological information
10/09/2002	EP1246940A2 Chemotherapeutant screening method
10/09/2002	EP1246925A1 Di- or oligomer of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins
10/09/2002	EP1246923A2 Dna modification proteins
10/09/2002	EP1246919A1 Progenitor cell preservation factors and related methods and products
10/09/2002	EP1246918A2 Secreted proteins
10/09/2002	EP1246917A2 Human stra6 polypeptides
10/09/2002	EP1246901A1 Methods for protein transfer
10/09/2002	EP1246843A1 Novel fgf homolog zfgf12
10/09/2002	EP1246842A1 Nk cell receptor polynucleotides, polypeptides, and antibodies
10/09/2002	EP1246841A1 Transcription factors containing two potential dna binding motifs
10/09/2002	EP1246840A2 Human and parasite orphan receptor proteins
10/09/2002	EP1246826A1 Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
10/09/2002	EP1246824A1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof
10/09/2002	EP1246823A1 Pyrimidine and triazine kinase inhibitors
10/09/2002	EP1246808A1 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation
10/09/2002	EP1246807A2 Novel hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines
10/09/2002	EP1246648A2 Dendrimer-photosensitizer complexes for medical applications
10/09/2002	EP1246646A2 Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen
10/09/2002	EP1246644A1 Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
10/09/2002	EP1246637A2 Methods of modulation of the immune system
10/09/2002	EP1246630A1 Compositions and methods for facilitating skin growth and managing skin conditions
10/09/2002	EP1246629A1 Methods of using electron active compounds for managing cancer
10/09/2002	EP1246627A2 Polyanhydrides with biologically active degradation products
10/09/2002	EP1246623A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof
10/09/2002	EP1246621A1 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
10/09/2002	EP1246620A1 Substituted acylhydroxamic acids and method of reducing tnf-g(a) levels
10/09/2002	EP1246617A2 Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
10/09/2002	EP1246608A1 Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
10/09/2002	EP1246597A2 Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
10/09/2002	EP1246538A1 Thickened oil compositions of edible oil
10/09/2002	EP1115391B1 Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
10/09/2002	EP1100804B1 Tin polyoxaalkanecarboxylates and compositions containing them
10/09/2002	EP1049467B1 Celecoxib compositions
10/09/2002	EP0964856B1 Bicyclic amino acids
10/09/2002	EP0868434B1 Anti-idiotypic antibodies of vascular endothelial growth factor and use thereof as drugs
10/09/2002	EP0833620B1 Fgfr3 as a marker for mesenchymal skeletal progenitor cells
10/09/2002	EP0804562B1 Connective tissue growth factor-2
10/09/2002	EP0754189B1 Receptor modulating agents and methods relating thereto
10/09/2002	EP0679082B1 C10 taxane derivatives and pharmaceutical compositions
10/09/2002	CN1373774A Compositions isolated from skin cells and methods for their use
10/09/2002	CN1373771A Vaccine
10/09/2002	CN1373769A Betulinic acid derivs, having antiangiogenic activity, processes for producing such derivs. and their use for treating tumor associated angiogenesis

1 ... 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 1671 1672 1673 1674 ... 2211